Website
News25/Ratings12
News · 26 weeks57-43%
2025-10-262026-04-19
Mix2890d
- Insider10(36%)
- SEC Filings6(21%)
- Analyst5(18%)
- Other5(18%)
- Earnings2(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Kyrillos Jean-Claude4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- SECSEC Form DEF 14A filed by Tandem Diabetes Care Inc.DEF 14A - TANDEM DIABETES CARE INC (0001438133) (Filer)
- SECSEC Form DEFA14A filed by Tandem Diabetes Care Inc.DEFA14A - TANDEM DIABETES CARE INC (0001438133) (Filer)
- PRTandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial markets close on Thursday, May 7, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI870b
- SECSEC Form PRE 14A filed by Tandem Diabetes Care Inc.PRE 14A - TANDEM DIABETES CARE INC (0001438133) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tandem Diabetes Care Inc.SCHEDULE 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
- ANALYSTTandem Diabetes Care upgraded by Truist with a new price targetTruist upgraded Tandem Diabetes Care from Hold to Buy and set a new price target of $35.00
- INSIDERSEC Form 4 filed by Novara Mark David4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- ANALYSTTandem Diabetes Care upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Tandem Diabetes Care from Neutral to Overweight and set a new price target of $33.00
- INSIDEREVP & CHIEF COMMERCIAL OFFICER Novara Mark David sold $46 worth of shares (2 units at $22.81), decreasing direct ownership by 0.01% to 35,969 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- PRTandem Mobi Now Compatible with Android SmartphonesTandem Diabetes Care expands connected-care ecosystem by adding Android platform Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system,1 can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304073769/en/Tandem Mobi Now Compatible with Android Smartphones in U.S. "By expanding to Android, we're broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes,"
- SECTandem Diabetes Care Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
- PRTandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of $200.0 million aggregate principal amount of notes. Tandem also granted the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the first date on
- PRTandem Diabetes Care Announces Proposed Private Placement of Convertible NotesTandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Tandem also intends to grant the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $30.
- ANALYSTTandem Diabetes Care upgraded by Lake Street with a new price targetLake Street upgraded Tandem Diabetes Care from Hold to Buy and set a new price target of $50.00
- ANALYSTTandem Diabetes Care upgraded by BofA Securities with a new price targetBofA Securities upgraded Tandem Diabetes Care from Underperform to Neutral and set a new price target of $30.00
- INSIDERChief Technology Officer Carpenter Rick converted options into 2,334 shares and covered exercise/tax liability with 1,312 shares, increasing direct ownership by 4% to 25,274 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP, Chief Strategy Officer Gasser Elizabeth Anne converted options into 2,600 shares and covered exercise/tax liability with 1,534 shares (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP & Chief Admin. Officer Morrison Susan converted options into 2,600 shares and covered exercise/tax liability with 882 shares, increasing direct ownership by 4% to 42,635 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 77 shares and covered exercise/tax liability with 62 shares, increasing direct ownership by 0.04% to 35,971 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERPRESIDENT & CEO Sheridan John F converted options into 11,454 shares and covered exercise/tax liability with 4,363 shares, increasing direct ownership by 6% to 124,691 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP & CHIEF FINANCIAL OFFICER Vosseller Leigh covered exercise/tax liability with 1,235 shares and converted options into 2,998 shares, increasing direct ownership by 5% to 39,411 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDEREVP & Chief Legal Officer Hansen Shannon Marie converted options into 3,065 shares and covered exercise/tax liability with 1,263 shares, increasing direct ownership by 8% to 23,276 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- SECSEC Form 10-K filed by Tandem Diabetes Care Inc.10-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
- SECTandem Diabetes Care Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)